Contact your healthcare provider immediately if you experience: Severe or persistent abdominal pain , particularly if localized to the upper abdomen or accompanied by back pain, which could indicate pancreatitisa rare but serious adverse effect documented in tirzepatide clinical trials Right upper quadrant pain, fever, or yellowing of skin/eyes , which may indicate acute gallbladder disease, a known risk with tirzepatide therapy Persistent nausea and vomiting that prevents adequate oral intake or leads to signs of dehydration (decreased urination, dizziness, dry mouth, extreme thirst) Severe diarrhea lasting more than 48 hours or accompanied by fever, bloody stools, or severe cramping, which may indicate gastrointestinal infection or other complications Severe abdominal distention, inability to pass gas or stool, and persistent vomiting , which could indicate intestinal obstruction Inability to tolerate any food or liquids for more than 24 hours, as this poses risks for dehydration and electrolyte imbalances Unexplained weight loss beyond expected therapeutic effects, or difficulty maintaining adequate nutrition Patients taking tirzepatide with insulin or sulfonylureas should also be alert for hypoglycemia symptoms (shakiness, dizziness, sweating, confusion) and seek prompt care if severe

If you are approved for the program, youll be enrolled promptly and will need to visit the Artemedica clinic weekly for injections and progress check-ins
Ozempic 0.25 mg, 0.5 mg/dosis: Un ml de solucin contiene 1.34 mg de semaglutida
Inhibition of Glucagon Release : Liver glucose inhibits glucagon hormone, which means it decreases blood sugar levels
She has a Masters Degree in Public Health from UCLA, with a focus on behavioral health and education